Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020

Administered by Department of Health, Disability and Ageing

Legislation au F2020L00373 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

Issued by the Minister for Health

 

Health Insurance Act 1973

 

Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020

 

Subsection 3C(1) of the Health Insurance Act 1973 (the Act) provides that the Minister may, by legislative instrument, determine that a health service not specified in an item in the pathology services table (the Table) shall, in specified circumstances and for specified statutory provisions, be treated as if it were specified in the Table.

 

The Table is set out in the regulations made under subsection 4A(1) of the Act.  The most recent version of the regulations is the Health Insurance (Pathology Services Table) Regulations 2019.

 

This instrument relies on subsection 33(3) of the Acts Interpretation Act 1901 (AIA).  Subsection 33(3) of the AIA provides that where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character (including rules, regulations or by-laws), the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument.

 

Purpose

The purpose of the Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020 (the Amendment Determination) is to amend the Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020 to increase the Medicare benefits paid for SARS-COV-2 tests.

 

The Government has decided to increase the Medicare rebate for the SARS-COV-2 test.  The higher Medicare rebate will be payable under new Medicare items. New item 69479 provides a rebate for a pathology service undertaken for a private patient in a recognised (public) hospital or by a prescribed laboratory.  New item 69480 provides a rebate for undertaking the pathology test for any other patient. Old item 69485 has accordingly been replaced.  Two supplementary Medicare items will also be created so that SARS-CoV-2 tests provided between 13 March 2020 and 31 March 2020 can claim an additional amount equivalent to the difference between the fee for 69485 and the new fees for items 69479 and 69480.  There is no retrospective imposition on the public, only upon the Commonwealth.

Consultation

Consultation on these items was undertaken with the Royal College of Pathologists of Australasia and Australian Pathology.

 

Details of the Amendment Determination are set out in the Attachment.

The Amendment Determination commences on 1 April 2020. The Determination is a legislative instrument for the purposes of the Legislation Act 2003.

 

Authority:     Subsection 3C(1) of the

 Health Insurance Act 1973

ATTACHMENT

 

Details of the Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020

 

Section 1 – Name

 

Section 1 provides for the Amendment Determination to be referred to as the Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020

 

Section 2 – Commencement

 

Section 2 provides that the Amendment Determination commences on 1 April  2020.

 

Section 3 – Amendment of Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020

 

Section 3 provides that Schedule 1 of the Amendment Determination amends the Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020.

 

Section 4 - Authority

 

Section 4 provides that the Determination is made under subsection 3C(1) of the Health Insurance Act 1973.

 

Schedule – Relevant services

 

The Schedule incorporates the new items into section 7 to specify both the existing item and the new items in clause 1.7(2)(a) to exclude each test from being within a set of pathology services.

 

The Schedule further specifies the amended service and the associated fee for items 69479 and existing item 69480, whilst removing the current item 69485.


Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

 

Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020

 

This instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Determination

The purpose of the Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No.2) Determination 2020 (the Amendment Determination) is to amend the Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020 to replace one item with 2 new items for testing for SARS-COV-2.

 

The new items will commence on 30 March 2020.

 

Medical practitioners and pathologists have the ability to test for SARS-COV-2 and other respiratory viruses in the same single patient episode if, in their medical opinion, it is appropriate to do so.

 

Human rights implications

This instrument engages Articles 9 and 12 of the International Covenant on Economic Social and Cultural Rights (ICESCR), specifically the rights to health and social security.

The Right to Health

The right to the enjoyment of the highest attainable standard of physical and mental health is contained in Article 12(1) of the ICESCR. The UN Committee on Economic Social and Cultural Rights (the Committee) has stated that the right to health is not a right for each individual to be healthy, but is a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health.

The Committee reports that the ‘highest attainable standard of health’ takes into account the country’s available resources. This right may be understood as a right of access to a variety of public health and health care facilities, goods, services, programs, and conditions necessary for the realisation of the highest attainable standard of health.

The Right to Social Security

The right to social security is contained in Article 9 of the ICESCR. It requires that a country must, within its maximum available resources, ensure access to a social security scheme that provides a minimum essential level of benefits to all individuals and families that will enable them to acquire at least essential health care. Countries are obliged to demonstrate that every effort has been made to use all resources that are at their disposal in an effort to satisfy, as a matter of priority, this minimum obligation.

The Committee reports that there is a strong presumption that retrogressive measures taken in relation to the right to social security are prohibited under ICESCR. In this context, a retrogressive measure would be one taken without adequate justification that had the effect of reducing existing levels of social security benefits, or of denying benefits to persons or groups previously entitled to them. However, it is legitimate for a Government to re-direct its limited resources in ways that it considers to be more effective at meeting the general health needs of all society, particularly the needs of the more disadvantaged members of society.

Analysis

This instrument advances the right to health and the right to social security by ensuring people who may have been affected by COVID-19 can access pathology services for specific testing of the virus, which are clinically effective, safe and cost-effective.

Conclusion

This instrument is compatible with human rights as it maintains the right to health and the right to social security.

 

David Weiss

First Assistant Secretary

Medical Benefits Division

Health Financing Group

Department of Health

Overview

The Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020 is an instrument enacted to address the financial burden of COVID-19 pathology testing on the Australian community and healthcare system. This Determination, issued under the authority of the Health Insurance Act 1973, aims to amend the existing Medicare benefits for SARS-COV-2 tests to better align with the current clinical practices and financial realities. The primary policy objective of this instrument is to ensure equitable access to vital health services during the COVID-19 pandemic, thereby safeguarding the right to health and social security as recognised by the International Covenant on Economic, Social and Cultural Rights. This Amendment Determination introduces new Medicare items for pathology services related to COVID-19, replacing the previous item to better reflect the costs and services provided, and ensuring that the financial impact is borne by the Commonwealth rather than the public.

Scope and Application

The Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020 amends the Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020 to enhance the Medicare benefits for SARS-CoV-2 tests. This amendment applies to medical practitioners and pathologists who perform pathology tests for COVID-19, specifically targeting those tests conducted for private patients in recognised hospitals or by prescribed laboratories, and for any other patients. The Determination is a legislative instrument under the Health Insurance Act 1973, effective from 1 April 2020. It introduces two new Medicare items, 69479 and 69480, to replace the existing item 69485, ensuring higher rebates for the specified tests. Importantly, the Amendment Determination does not impose any retrospective costs on the public, only on the Commonwealth. Additionally, it incorporates supplementary Medicare items to account for tests performed between 13 March 2020 and 31 March 2020, providing an additional rebate equivalent to the difference between the fee for 69485 and the new fees for items 69479 and 69480. This Amendment Determination is compatible with human rights, specifically engaging with Articles 9 and 12 of the International Covenant on Economic, Social and Cultural Rights, by ensuring equitable access to health services and social security for those affected by COVID-19.

Key Provisions

The Health Insurance (Section 3C Pathology Services – COVID-19) Amendment (No. 2) Determination 2020 (the Amendment Determination) primarily amends the Health Insurance (Section 3C Pathology Services – COVID-19) Determination 2020 to adjust the Medicare benefits for SARS-COV-2 tests. Specifically, it introduces two new Medicare items, 69479 and 69480, to replace the existing item 69485. These changes are outlined in Section 3 of the Amendment Determination. The new items will provide higher rebates for pathology services related to SARS-COV-2 testing, ensuring that the services are treated as if they were specified in the pathology services table of the Health Insurance Act 1973 (the Act). This amendment ensures that the services are covered under the Medicare system with increased financial support from the government. The Amendment Determination imposes obligations on medical practitioners, pathologists, and laboratories to adhere to the new Medicare items for SARS-COV-2 testing. These entities must ensure that they bill patients according to the new rates specified in the Amendment Determination. Additionally, they must ensure that the pathology services provided are clinically effective, safe, and cost-effective, as per the requirements of the Health Insurance Act 1973. By doing so, they contribute to the government’s effort to manage the COVID-19 pandemic efficiently. There are no specific offences, penalties, or civil/criminal consequences outlined in the Amendment Determination for breaches of the provisions. However, non-compliance with the Health Insurance Act 1973 or the failure to adhere to the Medicare items as specified could potentially lead to legal actions under the general provisions of the Act. Such actions might include fines or other penalties as prescribed by the Act. The determination itself focuses on providing clarity and ensuring that the necessary services are adequately reimbursed, thereby supporting the health care system during the COVID-19 crisis.

Legal classification tags

Area of Law
Health Law
Instrument
Determination
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.